GlassScriptPhysician profile
Michelle A Cholankeril
NPI 1801056155
$4,457.83
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $310 · 2021: $321 · 2022: $622 · 2023: $2,331 · 2024: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.07 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,089.95 | 2023-2024 | Cabometyx |
| Genzyme Corporation | $311.83 | 2019-2024 | |
| Daiichi Sankyo INC. | $289.72 | 2019-2024 | Injectafer, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $282.39 | 2019-2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $214.82 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $193.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $187.23 | 2019-2023 | Keytruda |
| Seagen INC. | $171.87 | 2021-2023 | Tukysa |
| Gilead Sciences, INC. | $156.63 | 2022-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $155.16 | 2019-2023 | Lynparza |
| Lilly USA, LLC | $141.49 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Taiho Oncology, INC. | $127.03 | 2021-2024 | |
| Eisai INC. | $120.80 | 2019-2024 | |
| Celgene Corporation | $111.18 | 2020-2024 | Reblozyl |
| Dendreon Pharmaceuticals LLC | $99.51 | 2019-2024 | Provenge |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $90.51 | 2022-2023 | Lumakras |
| Genentech USA, INC. | $81.93 | 2019-2024 | Lunsumio, Polivy, Gazyva |
| Novartis Pharmaceuticals Corporation | $81.62 | 2019-2024 | |
| Pfizer INC. | $73.92 | 2019-2024 | |
| Janssen Biotech, INC. | $71.19 | 2019-2023 | Erleada, Darzalex, Tecvayli |
| Incyte Corporation | $62.09 | 2020-2023 | Jakafi |
| Novocure INC. | $46.68 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $31.90 | 2023-2024 | Ultomiris |
| Janssen Scientific Affairs, LLC | $29.46 | 2019-2022 | |
| Foundation Medicine, INC. | $28.96 | 2022 | |
| Abbvie INC. | $28.01 | 2024 | |
| Astellas Pharma US INC | $27.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $25.31 | 2020-2022 | |
| Kite Pharma, INC. | $20.55 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.10 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $15.40 | 2024 | Fruzaqla |
| Servier Pharmaceuticals LLC | $15.22 | 2024 | |
| Global Blood Therapeutics, INC. | $15.00 | 2022 | |
| Genmab U.S., INC. | $14.79 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.52 | 2019 | |
| Recordati_rare_diseases_inc. | $12.78 | 2023 | Sylvant |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cholankeril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.